Clene (NASDAQ:CLNN) Director David Matlin Purchases 33,333 Shares of Stock

Clene Inc. (NASDAQ:CLNN) Director David Matlin purchased 33,333 shares of Clene stock in a transaction on Tuesday, January 13th. The shares were acquired at an average cost of $6.50 per share, for a total transaction of $216,664.50. Following the completion of the transaction, the director owned 477,824 shares of the company’s stock, valued at $3,105,856. This represents a 7.50% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Clene Stock Down 1.5%

Shares of CLNN stock traded down $0.08 during mid-day trading on Tuesday, reaching $5.10. The company’s stock had a trading volume of 277,268 shares, compared to its average volume of 132,371. The firm has a market capitalization of $52.68 million, a PE ratio of -1.50 and a beta of 0.87. The company’s 50 day simple moving average is $7.54 and its 200-day simple moving average is $6.45. Clene Inc. has a 12-month low of $2.28 and a 12-month high of $13.50.

Clene (NASDAQ:CLNN) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.25). The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.06 million. As a group, research analysts anticipate that Clene Inc. will post -5.19 EPS for the current fiscal year.

Clene News Roundup

Here are the key news stories impacting Clene this week:

• Positive Sentiment: Clene announced the FDA has granted an in‑person Type C meeting later this quarter and released additional CNM‑Au8 biomarker data that the company says could support a potential NDA filing — a clear regulatory catalyst that could derisk the development program if the meeting goes well. Clene Announces Additional CNM-Au8 Biomarker Data Supporting Potential NDA Filing for Upcoming In-Person FDA Meeting
• Neutral Sentiment: Reported short‑interest figures for January appear to show 0 shares and a days‑to‑cover of 0.0 — likely a reporting/data anomaly rather than a meaningful change in market positioning; don’t rely on that data point alone.
• Negative Sentiment: Major shareholder Chidozie Ugwumba has been actively selling in early January, including a 32,705‑share sale (avg. ~$5.50) disclosed Jan. 12 and multiple other disposals totaling tens of thousands of shares across the first two weeks of January. The sales have reduced his stake (one filing shows a ~4.41% decrease after the 32,705‑share trade), which can pressure the stock and signal liquidity needs or portfolio rebalancing. Insider Selling: Clene (NASDAQ:CLNN) Major Shareholder Sells 3,195 Shares of Stock

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Lunt Capital Management Inc. raised its stake in shares of Clene by 71.2% in the 2nd quarter. Lunt Capital Management Inc. now owns 51,010 shares of the company’s stock valued at $199,000 after purchasing an additional 21,217 shares in the last quarter. Jones Financial Companies Lllp bought a new stake in Clene in the third quarter valued at about $29,000. Scoggin Management LP raised its stake in Clene by 75.1% during the third quarter. Scoggin Management LP now owns 250,000 shares of the company’s stock valued at $1,506,000 after buying an additional 107,250 shares in the last quarter. Finally, Jane Street Group LLC acquired a new stake in Clene during the second quarter valued at approximately $47,000. 23.28% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have recently commented on CLNN. Weiss Ratings reissued a “sell (d-)” rating on shares of Clene in a research report on Friday. Benchmark reaffirmed a “buy” rating on shares of Clene in a research note on Thursday, December 4th. D. Boral Capital reiterated a “buy” rating and issued a $23.00 price objective on shares of Clene in a report on Friday. Finally, UBS Group restated a “buy” rating on shares of Clene in a research note on Wednesday, December 3rd. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $32.60.

Clene Company Profile

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).